INS and cancer: Researchers should consider specifically focusing on whether drugs targeting the insulin/IGF system and its downstream signaling molecules may particularly benefit obese cancer patients, who generally have higher circulating insulin and IGF-I levels as well as a greater risk of treatment failure and cancer mortality.